DISC-1459 not checked
Disc Medicine, Inc · RO4917838
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Erythropoietic Protoporphyria
- Main trialPhase 2/3
- “This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.”In the company’s words, NCT05883748 on ClinicalTrials.gov
- Other names
- Bitopertin · RO4917838
Other drugs for Erythropoietic Protoporphyria
- PORT-77Portal Therapeutics, Inc. · Phase 2/3
Coming up1
- Jun 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Enrolling by invitation | Jun 2028 | HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP | |
| Phase 3Completed | 8 Sep 2026 | Study of Bitopertin in Participants With EPP or XLP (APOLLO) | |
| Phase 2Completed | 20 Feb 2024 | Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026